The facility is structured in multiple tranches rather than as a single draw. It includes an initial term loan of $75 million funded at closing; a potential additional $75 million draw at Intellia's option upon FDA approval of its biologics license application (BLA) for lonvoguran ziclumeran (lonvo-z) prior to a certain date; three potential additional $40 million draws at Intellia's option upon achieving certain revenue targets for lonvo-z prior to certain dates (totaling up to $120 million, consistent with the press release's reference to additional tranches totaling up to $225 million tied to the FDA-approval and revenue milestones); a potential additional $30 million draw at Intellia's option upon achieving an equity fundraising target prior to a certain date; and an uncommitted additional incremental facility of up to $100 million subject to mutual agreement among Intellia and the lenders. The press release additionally characterizes the facility as non-dilutive.
The Credit Facility matures on September 4, 2031. Loans bear interest, payable monthly, at a rate per annum equal to the greater of (a) 3.00% or (b) the one-month SOFR rate applicable to the period, plus an applicable margin of 6.15%. Intellia is also required to pay customary commitment, administrative, undrawn amount and facility fees. Intellia may prepay amounts owed prior to the maturity date subject to a repayment premium or exit fee, as applicable, plus accrued interest on amounts repaid or prepaid; the facility is also subject to customary mandatory prepayments from proceeds of indebtedness and certain asset sales and casualty events. The 8-K does not specify the exact dollar amount or percentage of the repayment premium or exit fee.
Proceeds of the Credit Facility are to be used for Intellia's working capital needs and general corporate purposes. The 8-K does not disclose that this facility refinances any prior specific credit facility; no prior facility is named.
All obligations under the Credit Agreement are secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all of Intellia's assets, including its intellectual property. The Credit Agreement is not covenant-lite: it contains customary financial covenants, including a requirement to maintain liquidity of at least $50 million in controlled accounts until FDA approval of the lonvo-z BLA, and, thereafter, a requirement to either achieve certain revenue targets, maintain certain market capitalization thresholds, or maintain outstanding loan principal in cash equivalents in controlled accounts. It also contains negative covenants that, subject to certain exceptions, restrict Intellia's ability to incur additional indebtedness, grant liens, make investments (including acquisitions), effect mergers or consolidations, engage in asset sales and licensing transactions, pay dividends, terminate or modify certain material agreements, and pay subordinated indebtedness, among other customary restrictions. Exceptions to the indebtedness and lien covenants permit Intellia to enter into synthetic royalty transactions, subject to certain restrictions in the Credit Agreement. The Credit Agreement contains customary events of default, including payment defaults, material inaccuracy of representations and warranties, covenant defaults, bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against Intellia and its subsidiaries, and change of control.
TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed, confirming OrbiMed as the lender/creditor side of the transaction (via its affiliated funds OrbiMed Royalty & Credit Opportunities IV, LP and V, LP, the latter also serving as administrative agent).
The 8-K states that the full Credit Agreement itself had not yet been filed as of the September 4, 2026 report; Intellia disclosed that it will be filed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. As of this update, that 10-Q has not yet been filed with the SEC (the most recent 10-Q on file is for the quarter ended June 30, 2026, filed August 6, 2026), so the complete text of the Credit Agreement, including the precise pricing grid (if any), full definitions of the revenue/market-cap thresholds, and the exact repayment premium or exit fee schedule, remains undisclosed. The deal status remains announced; no closing, draw, or termination beyond the initial $75 million funded at the Closing Date has been confirmed in subsequent filings.